{"id":"tociliziumab-group","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Liver enzyme elevations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the interleukin-6 receptor, preventing the activation of the receptor and subsequent signaling pathways that lead to inflammation. This results in a reduction in the production of pro-inflammatory cytokines and a decrease in the severity of inflammatory responses.","oneSentence":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:06.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT05002517","phase":"PHASE3","title":"Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab","status":"UNKNOWN","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2020-09-03","conditions":"COVID-19 Pneumonia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tociliziumab group","genericName":"Tociliziumab group","companyName":"Biogipuzkoa Health Research Institute","companyId":"biogipuzkoa-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}